Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo may slash radiation harm in rare lymphoma

NCT ID NCT07554482

Disease control Sponsor: Beijing Tongren Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug selinexor to a lower dose of radiation can treat early-stage NK/T-cell lymphoma just as well as standard high-dose radiation, but with fewer side effects. About 34 people who have not had prior treatment will receive chemotherapy first, then selinexor plus 40 Gy radiation. The goal is to see if this approach keeps the cancer under control while reducing mouth sores and dry mouth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 34 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 to 75 years, regardless of gender. * Pathologically confirmed extranodal NK/T-cell lymphoma (ENKTCL). * Ann Arbor stage I-II disease with primary lesion located in the nasal cavity or upper aerodigestive tract (UADT). * Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. * Treatment-naïve patients with no prior radiotherapy, chemotherapy or targeted therapy. * Adequate major organ function as follows: * Hematopoietic function: absolute neutrophil count (ANC) ≥1.5×10⁹/L, platelet count (PLT) ≥100×10⁹/L, hemoglobin (Hb) ≥90 g/L. * Hepatic function: total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN), alanine transaminase (ALT) / aspartate transaminase (AST) ≤2.5×ULN. * Renal function: serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance rate ≥60 mL/min. * Cardiac function: left ventricular ejection fraction (LVEF) ≥50%. * Expected overall survival ≥6 months. * Voluntarily sign the written informed consent form. Exclusion Criteria: * Non-nasal type ENKTCL, or primary lesions outside the upper aerodigestive tract (UADT), including skin, gastrointestinal tract, lung and other sites. * Patients with Ann Arbor stage III-IV disease. * Central nervous system involvement. * History of prior malignant tumors, excluding non-melanoma skin cancer or cervical carcinoma in situ cured for more than 5 years. * Active infections, including active hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infection. * Severe complications, such as uncontrolled diabetes mellitus and severe cardiopulmonary diseases. * Pregnant or lactating women. * Hypersensitivity or contraindication to any investigational drugs in this study. * Concurrent participation in other interventional clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early-stage extranodal NK/T-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

extranodal nasal NK/T cell lymphoma Lymphoma, Extranodal NK-T-Cell

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Extranodal NK-T-cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.